{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:46:59Z","timestamp":1772160419241,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The pandemic of coronavirus disease 2019 (COVID\u201019) has caused heavy burdens on national healthcare systems. Nirmatrelvir\u2010ritonavir (Paxlovid) may be one of the most promising therapeutic drugs, with reports of up to 89% reduction rates in hospitalization risk and death among patients with mild\u2010to\u2010moderate COVID\u201019 who are at risk of developing severe disease. However, limited studies have investigated the effects of this class of drugs on viral clearance and length of hospital stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we retrospectively analyzed the characteristics of patients infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102) and investigated the effects of oral nirmatrelvir\u2010ritonavir on viral clearance and length of hospital stay in mild\u2010to\u2010moderate COVID\u201019 patients at high risk for progression to severe disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median SARS\u2010CoV\u20102 negative conversion time was 16 (13\u201320) versus 13 (10\u201316)\u00a0days (control group versus nirmatrelvir\u2010ritonavir group,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u20090.001), the median length of hospital stay was 13 (10\u201316) versus 12 (13\u201314) days (control group versus nirmatrelvir\u2010ritonavir group,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), and the SARS\u2010CoV\u20102 negative conversion time and length of hospital stay were significantly shorter in the nirmatrelvir\u2010ritonavir group than in the control group. When controlling for hypertension, chronic kidney disease, severity status of COVID\u201019, use of antibiotic agent, and COVID\u201019 vaccine received, multiple stepwise linear regression analysis showed that nirmatrelvir\u2010ritonavir treatment was negatively associated with the SARS\u2010CoV\u20102 negative conversion time and length of hospital stay.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nirmatrelvir\u2010ritonavir reduces the viral clearance time and length of hospital stay in hospitalized patients with COVID\u201019. Nirmatrelvir\u2010ritonavir might be a promising drug to reduce the virus load and the heavy burden of healthcare systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/irv.13095","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T01:48:48Z","timestamp":1675388928000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The effect of nirmatrelvir\u2010ritonavir on viral clearance and length of hospital stay in patients infected with SARS\u2010CoV\u20102 omicron variants"],"prefix":"10.1111","volume":"17","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Shidong Hospital, Yangpu District Shidong Hospital Affiliated to University of Shanghai for Science and Technology  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xubo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation medicine, Shidong Hospital, Yangpu District Shidong Hospital Affiliated to University of Shanghai for Science and Technology  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinbing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shidong Hospital, Yangpu District Shidong Hospital Affiliated to University of Shanghai for Science and Technology  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenying","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shidong Hospital, Yangpu District Shidong Hospital Affiliated to University of Shanghai for Science and Technology  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6811-5646","authenticated-orcid":false,"given":"Liuliu","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shidong Hospital, Yangpu District Shidong Hospital Affiliated to University of Shanghai for Science and Technology  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.37201\/req\/158.2021"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7125e2"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac180"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(22)00430\u20103"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)01586\u20100"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(22)00507\u20102"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119658"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27588"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","unstructured":"CharnessM GuptaK StackG et al.Symptomatic omicron SARS\u2010CoV\u20102 infection following early suppression with nirmatrelvir\/ritonavir. PREPRINT (Version 3) available at Research Square.2022.","DOI":"10.21203\/rs.3.rs-1588371\/v2"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","unstructured":"WangL BergerNA DavisPB KaelberDC VolkowND XuR.COVID\u201019 rebound after Paxlovid and Molnupiravir during January\u2013June 2022. medRxiv: the preprint server for health sciences.2022.","DOI":"10.1101\/2022.06.21.22276724"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.06.011"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.08.012"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.13095","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/irv.13095","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.13095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T10:14:27Z","timestamp":1692267267000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.13095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/irv.13095"],"URL":"https:\/\/doi.org\/10.1111\/irv.13095","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/IRV.13095\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13095\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13095\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.13095\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"2022-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13095"}}